Plain-English translation of NCT05679583 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a type of focused radiation therapy called stereotactic body radiation therapy (SBRT) can help people with resectable pancreatic cancer when given before surgery. You would receive this radiation treatment 2 to 4 weeks before your surgery, then receive chemotherapy for 6 months after surgery. The goal is to see if adding this radiation therapy improves survival and reduces the chance of cancer coming back.
Pancreatic cancer is difficult to treat even when it can be surgically removed, with many patients experiencing recurrence. Recent research suggests that adding radiation therapy before surgery may help improve survival rates, but this hasn't been thoroughly studied in this patient population.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would first receive focused radiation therapy (SBRT) as an outpatient treatment over a short period. Then, 2 to 4 weeks later, you would have surgery to remove the cancer. After surgery, you would receive chemotherapy (cancer-fighting drugs) for about 6 months. Throughout the study, your doctors will monitor your health, do blood tests, and track how well the treatment is working.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
South Korea